NCT07907913Not yet recruiting
SLAMF1 Gene Expression in Ankylosing Spondylitis
Study of Signaling Lymphocytic Activation Molecule Family Member 1 (SLAMF1) Gene Expression in Patients With Ankylosing Spondylitis
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This cross-sectional study aims to evaluate SLAMF1 gene expression levels in patients with ankylosing spondylitis compared with healthy controls.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 26 Oct 2026
- Start date
- 30 Oct 2026
- Primary completion date
- 30 Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Ankylosing spondylitis
- NCT number
- NCT07907913
What you commit to
- Study type: Observational
- Planned participants: 100
- From 30 Oct 2026 to the primary completion date, 30 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other concomitant systemic autoimmune or inflammatory rheumatic diseases
Other illness
- Active acute infection at blood sampling
- Current malignancy or active anticancer treatment
Who the study is looking for
- Adult Egyptian patients aged 18 years or older
- Diagnosed with ankylosing spondylitis according to established clinical criteria (patient group)
- Apparently healthy adults matched for age and sex (control group)
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.